3/4/2021 1:00:56 AM
Regeneron, Sanofi Announce FDA Accepted For Review SBLA For Dupixent For Children With Moderate-to-severe Asthma
2/25/2021 7:54:37 AM
Regeneron Says IDMC Finds Clear Efficacy For REGEN-COV In Phase 3 COVID-19 Outpatient Outcomes Trial
2/12/2021 1:08:18 AM
Regeneron: Libtayo Was Superior In Extending Overall Survival Vs Chemotherapy Even With High Crossover Rate
2/11/2021 5:12:09 PM
U.S. Federal Circuit Court Of Appeals Rules In Favor Of Regeneron And Sanofi In Praluent Patent Litigation
2/9/2021 5:25:34 PM
Regeneron, Sanofi: FDA Approves Libtayo As First Immunotherapy Indicated For Patients With Advanced BCC
2/5/2021 6:31:34 AM
Regeneron Q4 GAAP EPS $10.24 And Non-GAAP EPS $9.53
2/1/2021 10:01:13 AM
Regeneron : Dupixent Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases To Be Presented
1/27/2021 7:05:43 AM
Regeneron Says REGEN-COV Antibody Cocktail Is Active Against SARS-CoV-2 Variants Identified In UK, South Africa
1/26/2021 7:07:46 AM
Regeneron Reports Positive Interim Data With REGEN-COV Antibody Cocktail Used As Passive Vaccine To Prevent COVID-19